CCL8

Across TCGA pan-cancer cohorts, CCL8 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCL8 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CCL8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CCL8 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

GBM, CCRCC, and PDAC are the cancer types where CCL8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.364	0.770	.010	12	view →
CCRCC	OS	Median	II,III,IV	0.467	0.880	.017	1	view →
PDAC	OS	Median	II,III,IV	1.000	0.808	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCL8–GBM (OS)

Open the GBM breakdown →